How do you ensure the antibody binds to my epitope of interest and not to something else?

We design the screening process itself to build in proof of the desired specificity. Differential screening (binding to a target peptide but not a scrambled peptide) and counter-selection (removal of binders to a wild-type protein or unmodified version of the target) provides direct, empirical data to validate that the antibody is binding to the desired epitope.

What starting material do I need to provide to start an anti-epitope campaign?

The ideal starting materials are a clear definition of the epitope, the sequence of the target protein, and purified antigen of both the target and key counter-targets. If you don't have these, our team can help you with antigen design and production.

Can you discover antibodies to conformational epitopes?

Yes. For conformational epitopes, we typically use the full-length, correctly folded protein for positive selection and a denatured version or a mutated protein (where the epitope is disrupted) for counter-selection to isolate format-dependent binders.

Epitope Specific Antibody Discovery Services by Premade Library

Screening Services Workflow Premade Libraries Cases Related Services Why Choose Us? Work with Us FAQ

Move past off-target noise. We help you find high affinity antibodies that exclusively recognize your target epitope of interest, resulting in better functional control and deeper mechanistic understanding.

Isolate antibodies to conformational, linear, or discontinuous epitopes, including post-translational modifications and unique idiotopes.	De-risk early by proactively removing cross-reactivity to homologous regions, unmodified target, precursor forms, and different modification states at the start.
Modulate a desired biological activity at the exact site of interest. For instance, selectively activate or block an active cleft, an allosteric site or protein-protein interaction interface.	Dive deep into a 10¹¹ diverse human antibody library to find the needle in the haystack: the rare paratope that perfectly complements your target epitope, even the most complex or obscure.

Get Started - Request Your Quote Today

Anti-Epitope Antibody Discovery

Pinpoint Precision. Unrivaled Specificity.

Is your target's function dictated by a single, critical epitope? In modern drug discovery, binding is not enough. Functional innovation is increasingly contingent on antibodies that turn a specific molecular switch. The road to such precision, however, is paved with immunodominant distractions, conformational challenges, and cryptic molecular differences that can give you imprecise tools at best. At Creative Biolabs, we work with you to make your biological insights actionable. We design and execute your campaign to produce a panel of human antibodies with the level of specificity your program needs. And we do it with the speed and quality you need to keep the momentum going.

Request a Quote

The Screening Platform: A Strategy of Molecular Recognition Specialized Epitope Discovery Platforms

Specificity is not an accident; it is engineered. Our screening platform is architected to solve the fundamental challenge of epitope-specific discovery: distinguishing your target site from a universe of similar structures. We move beyond simple affinity selection, employing intelligent, multi-parameter strategies that use competition and subtraction to focus the vast power of our libraries onto a single molecular address. By designing campaigns around your epitope from day one, we eliminate the noise and deliver antibodies that answer your precise biological question, dramatically reducing downstream attrition and accelerating your path to validation.

Specialized Epitope Discovery Platforms

We offer dedicated workflows for the most demanding epitope-targeting challenges. Each platform utilizes a bespoke antigen and panning strategy to isolate antibodies with truly unique specificities.

Fig.1 Premade Antibody Library based TCR-Like Antibody Discovery. (Creative Biolabs Authorized)

Premade Antibody Library based TCR-Like Antibody Discovery
Isolate high-affinity antibodies that recognize a specific peptide presented within an MHC complex (pMHC), targeting the core of intracellular antigen presentation for novel immunotherapies.

Fig.2 Premade Antibody Library based Anti-Idiotype Antibody Discovery. (Creative Biolabs Authorized)

Premade Antibody Library based Anti-Idiotype Antibody Discovery
Develop highly specific antibodies that target the unique variable region (idiotope) of another antibody, essential for pharmacokinetic (PK), anti-drug antibody (ADA), and biomarker assays.

Fig.3 Premade Antibody Library based Anti-PTM Antibody Discovery. (Creative Biolabs Authorized)

Premade Antibody Library based Anti-PTM Antibody Discovery
Discover antibodies that bind exclusively to a specific post-translational modification (e.g., phosphorylation, acetylation, glycosylation), enabling the study and targeting of protein activation states.

Ask About Turnaround & Pricing

Epitope-Focused Discovery Workflow

Epitope Strategy & Antigen Design

In-depth epitope analysis; design of custom antigens (peptides, mutated proteins) and counter-selection reagents (wild-type protein, unmodified peptides) to ensure precision.
Subtractive Biopanning & Competitive Enrichment

Multiple rounds of negative selection against counter-targets; positive selection under competitive pressure (e.g., elution with soluble epitope peptide) to enrich for specificity.
Clone Validation & Epitope Verification

High-throughput screening of single clones for differential binding (e.g., peptide vs. protein; modified vs. unmodified; mutant vs. WT).
Sequence Analysis & Liability Profiling

NGS-driven analysis of outputs to identify sequence families.
Antibody Production & Biophysical Assessment

Expression of lead candidates in desired format; characterization of thermal stability, solubility, and aggregation propensity.
Affinity & Specificity Characterization

In-depth kinetic analysis (kon, koff, KD) of lead candidates against the target epitope and relevant off-targets; epitope binning.

Design Your Screening Strategy with Our Experts

Quick Library Selector

The search for a rare paratope requires a universe of possibilities. Our libraries provide the foundational diversity essential for discovering high-affinity binders to even the most subtle epitopes. Navigate our collection of premade antibody libraries to find the ideal source of diversity for your campaign.

Human Camel Llama Alpaca Humanized V_HH

Antibody Library ID	Display Technology	Library Format	Library Size
HuScL-6 ☆Highly Recommended	pIII-fusion, Phagemid Phage Display	Naïve scFv	2.1×10¹¹
HuScL-3S	pIII-fusion, Phagemid Phage Display	Semi-synthetic scFv	>1.0×10¹¹
HuFabL-4	pIII-fusion, Phagemid Phage Display	Naïve Fab	1.9×10¹⁰
HuFabssL-1	pIII-fusion, Phagemid Phage Display	Naïve & synthetic Fab	1.8×10¹⁰

Find the Perfect Library for Your Target

Case Study: High-Diversity Libraries, High-Impact Outcomes

High-Precision Epitope Discovery for Highly Homologous Targets

Project Background

The client sought to discover antibodies that specifically bind to a Target Protein (Isoform B) while avoiding cross-reactivity with its highly homologous Control Protein (Isoform A).

Challenge

The Target and Control share >96% amino acid sequence identity. The differentiating epitopes are limited to only a few amino acid residues, making this a classic needle in a haystack epitope discovery challenge. Standard screening often yields binders that recognize the conserved backbone shared by both proteins.

Our Solution: High-Stringency Subtractive Panning

We utilized our proprietary Premade Human scFv Library combined with a rigorous subtractive panning strategy:

Negative Selection	Heavy depletion against the Control Protein (Isoform A) was performed in every round to remove cross-reactive binders.
Positive Selection	Enrichment was targeted against the Biotinylated Target Protein (Isoform B).

We performed 5 rounds of biopanning to maximize stringency. While initial polyclonal enrichment showed only weak discrimination (reflecting the high homology), deep screening of single clones was employed to capture the rare specific binders.

Key Results

1. Identification of Unique Specific Binders
We randomly selected hundreds of single clones from the outputs for Monoclonal Phage ELISA.

Soluble ELISA identified 3 unique lead clones with distinct binding profiles.
While non-specific background binders were present (as expected with such high homology), the antibody candidates demonstrated significant positive binding to the Target Protein with markedly lower or negligible signals against the Control Homolog.

Fig.10 Graph illustrating the library screening outcomes. (Creative Biolabs Original)

Fig.11 Graph displaying the phage ELISA validation results. (Creative Biolabs Original)

Fig.12 Graph displaying the soluble ELISA validation results. (Creative Biolabs Original)

2. SPR Characterization (Affinity & Specificity)
To validate the epitope specificity and developability, the antibody candidate was produced in three different formats and analyzed via Surface Plasmon Resonance (SPR).

Affinity Differential

The SPR analysis confirmed a distinct Affinity Gap. The antibody bound to the Target Protein with nanomolar affinity 10^-7 M range), whereas binding to the Control Homolog was significantly weaker (micromolar range, 10^-6 M).

Format Stability

The specificity profile was maintained across all three formats (scFv, fusion, and full IgG), proving that the epitope recognition is intrinsic to the CDRs and not an artifact of the scaffold.

Ready to Build Your Success Story? Contact Us

Related Services

Find additional antibody discovery services tailored to your specific needs.

Fig.14 Functional human antibody discovery. (Creative Biolabs AI)

Functional Human Antibody Discovery

Fig.13 Anti-peptide/protein antibody discovery. (Creative Biolabs AI)

Anti-Peptide/Protein Antibody Discovery

Fig.15 Anti-Cell-based target antibody discovery. (Creative Biolabs AI)

Anti-Cell-based Target Antibody Discovery

Fig.16 Bi-functional antibody discovery. (Creative Biolabs AI)

Bi-functional Antibody Discovery

Fig.17 Cell-internalizing antibody discovery. (Creative Biolabs AI)

Cell-Internalizing Antibody Discovery

Fig.19 Antibody discovery for immunotherapy. (Creative Biolabs AI)

Antibody Discovery for Immunotherapy

Fig.20 Anti-disease-specific target antibody discovery. (Creative Biolabs AI)

Anti-Disease-Specific Target Antibody Discovery

Ask About Turnaround & Pricing

Why Choose Us?

Fig.21 Intellectual, not brute force. (Creative Biolabs AI)

Intellectual, not brute force

Our discovery and screening strategies are designed using custom antigens and counter-selection strategies to deliver you exactly the specificities you need.

Fig.22 Mechanism-Defined Discovery. (Creative Biolabs AI)

Mechanism-Defined Discovery

Target exactly the molecular features that underlie the biology you are studying and get back antibodies with higher functional performance and unambiguous mechanistic validation.

Fig.23 Proactive Specificity De-risking. (Creative Biolabs AI)

Proactive Specificity De-risking

By confronting cross-reactivity challenges at the very beginning of the discovery process, we save you months of downstream troubleshooting and prevent costly program delays.

Fig.24 From Question to Candidate, Faster. (Creative Biolabs AI)

From Question to Candidate, Faster

Our integrated platform, built on specialized expertise, accelerates discovery from a complex biological question to a suite of fully validated, epitope-specific IgG.

Fig.25 Transparent, Complete Data Package. (Creative Biolabs AI)

Transparent, Complete Data Package

Receive a full package of validated sequences and the data that proves their epitope specificity, so your team can feel confident in their validation data and make well-informed decisions.

Fig.26 Work as an Extension of Your Team. (Creative Biolabs AI)

Work as an Extension of Your Team

We view each collaboration as an opportunity to apply our expertise in solving your most challenging antibody discovery needs.

Customize Your Package - Get Pricing

Define Your Target. Discover Your Antibody.

Getting started is easy! To set up a call to discuss your project, provide us with as much of the following information as possible:

The type of epitope you are targeting (linear, conformational, PTM, etc.).
Sequence of the parent protein or molecule of interest.
Homologous or unmodified proteins and other key molecules for counter-selection.
The final intended application (therapeutic, diagnostic, research tool).
Desired deliverables and timelines.

FAQ

How do you ensure the antibody binds to my epitope of interest and not to something else?
We design the screening process itself to build in proof of the desired specificity. Differential screening (binding to a target peptide but not a scrambled peptide) and counter-selection (removal of binders to a wild-type protein or unmodified version of the target) provides direct, empirical data to validate that the antibody is binding to the desired epitope.
What starting material do I need to provide to start an anti-epitope campaign?
The ideal starting materials are a clear definition of the epitope, the sequence of the target protein, and purified antigen of both the target and key counter-targets. If you don't have these, our team can help you with antigen design and production.
Can you discover antibodies to conformational epitopes?
Yes. For conformational epitopes, we typically use the full-length, correctly folded protein for positive selection and a denatured version or a mutated protein (where the epitope is disrupted) for counter-selection to isolate format-dependent binders.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: